These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35368006)

  • 1. Letter to the editor: Triclosan in patients with inflammatory bowel disease.
    Peña-Cardelles JF
    Med Oral Patol Oral Cir Bucal; 2022 Sep; 27(5):e442-e443. PubMed ID: 35368006
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to editor: New onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease.
    Tamanini S; Fredi M; Crisafulli F; Lazzaroni MG; Tincani A; Franceschini F
    Clin Rheumatol; 2019 Feb; 38(2):609-610. PubMed ID: 30397839
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug treatment and psychological distress in inflammatory bowel disease: Response to Sovich's letter to the Editor.
    Berens S; Schaefert R; Baumeister D; Gauss A; Eich W; Tesarz J
    J Psychosom Res; 2020 May; 132():109971. PubMed ID: 32126338
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: immune-mediated inflammatory diseases and inflammatory bowel disease-are we ready for a Copernican revolution?
    Bezzio C; Alimenti E; Saibeni S
    Aliment Pharmacol Ther; 2022 Nov; 56(9):1429-1430. PubMed ID: 36221158
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter to the Editor: Feasibility and Efficiency of an E-Health Preadmission Assessment System for Intravenous Therapy in Inflammatory Bowel Disease.
    Pouillon L; Hoefkens E; Verheyen V; Bronswijk M; Van Olmen A; Van Dessel S; Siborgs N; Bossuyt P
    Inflamm Bowel Dis; 2020 Jan; 26(2):e11-e12. PubMed ID: 31793628
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to letter to the editor.
    Bressler B; Devlin S; Bernstein C; Singh H; Fedorak R
    Can J Gastroenterol Hepatol; 2014 Sep; 28(8):453-4. PubMed ID: 25229468
    [No Abstract]   [Full Text] [Related]  

  • 7. A Response to: Letter to the Editor Regarding 'Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland'.
    Aksan A; Schoepfer A; Juillerat P; Vavricka S; Bettencourt M; Ramirez de Arellano A; Gavata S; Morin N; Valentine WJ; Hunt B
    Adv Ther; 2022 Jan; 39(1):815-821. PubMed ID: 34846708
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter to the Editor Regarding 'Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland'.
    Muñoz M; Reinisch W
    Adv Ther; 2022 Jan; 39(1):811-814. PubMed ID: 34846707
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.
    Mahmoud R; Schultheiss JPD; Fidder HH; Oldenburg B
    Aliment Pharmacol Ther; 2022 Feb; 55(4):499-500. PubMed ID: 35092052
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter to the Editor: Re-Revisiting the Association Between Inflammatory Bowel Disease and Parkinson's Disease.
    Peter I; Dubinsky M; Xuan S; Chen N; Wang A
    Inflamm Bowel Dis; 2022 Jun; 28(6):e72. PubMed ID: 35267013
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to the Letter to the Editor: "Re-Revisiting the Association Between Inflammatory Bowel Disease and Parkinson's Disease".
    Coates MD; Ba DM; Liu G; Dalessio S; Leslie DL; Huang X
    Inflamm Bowel Dis; 2022 Jun; 28(6):e73-e74. PubMed ID: 35358300
    [No Abstract]   [Full Text] [Related]  

  • 12. Pediatric Patients With a Dual Diagnosis of Inflammatory Bowel Disease and Chronic Recurrent Multifocal Osteomyelitis: A Single-Centre Case Series - Response to Letter to the Editor.
    Dushnicky MJ; Beattie KA; Cellucci T; Heale L; Zachos M; Sherlock M; Batthish M
    J Pediatr Gastroenterol Nutr; 2022 May; 74(5):e129. PubMed ID: 35579882
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of Psychopathology.
    Taft TH; Quinton S; Tomasino K; Craven M; Guadagnoli L; Bedell A; Hanauer S
    Inflamm Bowel Dis; 2019 Aug; 25(9):e114. PubMed ID: 30989208
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs.
    Yin JQ; Wang BQ; Chen ZB; He HD; Huang SS; Wang WK; Wu J; Fu YH; Wang YL
    Aliment Pharmacol Ther; 2022 Apr; 55(7):882-883. PubMed ID: 35315104
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter to the Editor in Response to "Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease".
    Mc Gettigan N; Boland K; O'Toole A
    Inflamm Bowel Dis; 2022 May; 28(5):e59-e60. PubMed ID: 35512142
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs-authors' reply.
    Khalili H; Casey K
    Aliment Pharmacol Ther; 2022 Apr; 55(7):884. PubMed ID: 35315105
    [No Abstract]   [Full Text] [Related]  

  • 17. [Osteoporosis in chronic inflammatory bowel diseases--what is the value of fluoride therapy? Symposium: "Osteopenia, osteoporosis in chronic inflammatory bowel diseases". Saalfelden, 10 October 1998].
    Dtsch Med Wochenschr; 1998 Dec; 123(51-52 Suppl Osteoporos):1-4. PubMed ID: 9894480
    [No Abstract]   [Full Text] [Related]  

  • 18. The Influence of Triclosan on Biomarkers of Cardiovascular Risk in Patients in the Cardiovascular and Periodontal Study (CAPS): A Randomized Controlled Trial.
    Cullinan MP; Palmer JE; Faddy MJ; Westerman B; Carle AD; West MJ; Seymour GJ
    J Periodontol; 2015 Jul; 86(7):847-55. PubMed ID: 25741582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter: thiopurine blood monitoring for patients with inflammatory bowel disease.
    El-Matary W
    Aliment Pharmacol Ther; 2012 Mar; 35(6):742; author reply 743-4. PubMed ID: 22348522
    [No Abstract]   [Full Text] [Related]  

  • 20. 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?
    De Broe ME; Stolear JC; Nouwen EJ; Elseviers MM
    Nephrol Dial Transplant; 1997 Sep; 12(9):1839-41. PubMed ID: 9306332
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.